CA
AUTL

Clearstead Advisors’s Autolus Therapeutics AUTL Stock Holding History

Clearstead Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Hold
121,107
– – ﹤0.01% 1075
2026
Q1 		$167K Hold
121,107
– – ﹤0.01% 1021
2025
Q4 		$241K Hold
121,107
– – ﹤0.01% 884
2025
Q3 		$197K Hold
121,107
– – ﹤0.01% 887
2025
Q2 		$276K Buy
121,107
+30,000
+33% +$49.6K ﹤0.01% 797
2025
Q1 		$141K Hold
91,107
– – ﹤0.01% 908
2024
Q4 		$214K Sell
91,107
-5,000
-5% -$16.9K ﹤0.01% 829
2024
Q3 		$349K Hold
96,107
– – 0.01% 665
2024
Q2 		$334K Buy
+96,107
New +$415K 0.01% 641

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Clearstead Advisors's AUTL Position: Q2 2026 in Review

Clearstead Advisors held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 121,107 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #1075.

Clearstead Advisors first reported a position in AUTL in Q2 2024 and has held it in 9 quarters since. The position peaked at $349K in Q3 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Clearstead Advisors held 121,107 shares of Autolus Therapeutics worth $194K as of Q2 2026.
  • Clearstead Advisors left its Autolus Therapeutics share count unchanged in Q2 2026.
  • Autolus Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1075 holding.
  • Clearstead Advisors first reported a position in Autolus Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Clearstead Advisors's Autolus Therapeutics position peaked at $349K in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.